Skip to search formSkip to main contentSkip to account menu

TAK-475

Known as: TAK 475, TAK475 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

Lapaquistat Acetate

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2018
Review
2018
Efficacy and Safety of Tadalafil 5 mg Once Daily for the Treatment of Erectile Dysfunction After Robot-Assisted Laparoscopic Radical Prostatectomy: A 2-Year Follow-Up
2009
2009
Proč tak snadno-- : některé rodinné důvody sametové revoluce :sociologický esej
Review
2009
Review
2009
Pharmacologic Inhibition of Squalene Synthase and Other Downstream Enzymes of the Cholesterol Synthesis Pathway: A New Therapeutic Approach to Treatment of Hypercholesterolemia
Hypercholesterolemia is a major risk factor for the development of atherosclerotic vascular diseases. The most popular agents for… 
2008
2008
Lapaquistat acetate, a squalene synthase inhibitor, changes macrophage/lipid‐rich coronary plaques of hypercholesterolaemic rabbits into fibrous lesions
Inhibition of squalene synthesis could transform unstable, macrophage/lipid‐rich coronary plaques into stable, fibromuscular… 
2007
2007
Squalene synthase inhibition: A novel target for the management of dyslipidemia
A new class of compounds, known as squalene synthase inhibitors, has recently reached phase III clinical trials and may provide… 
Review
2006
Review
2006
Drug evaluation: TAK-475--an oral inhibitor of squalene synthase for hyperlipidemia.
Takeda Pharmaceutical Co Ltd is developing TAK-475, a squalene synthetase inhibitor from a series of 4,1-benzoxazepine-3-acetic… 
Highly Cited
2003
Highly Cited
2003
Comparing myotoxic effects of squalene synthase inhibitor, T-91485, and 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors in human myocytes.
Highly Cited
2003
Highly Cited
2003
Lipid‐lowering properties of TAK‐475, a squalene synthase inhibitor, in vivo and in vitro
Squalene synthase is the enzyme that converts farnesyl pyrophosphate to squalene in the cholesterol biosynthesis pathway. We… 
2003
2003
Lipid-lowering effects of TAK-475, a squalene synthase inhibitor, in animal models of familial hypercholesterolemia.
1999
1999
Proč tak snadno
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)